Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
03 Mai 2023 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in gene
therapies in the inner ear, announces that the Company’s
shareholders are invited to participate in the Combined General
Meeting, to be held on Wednesday, May 24, 2023, at 2 pm CET in the
premises of the hotel Square Louvois, located at 12, rue de
Louvois, 75002, Paris, France.
The prior notice of meeting comprising the agenda and draft
resolutions was published in the BALO (Bulletin des Annonces
Légales Obligatoires) on April 19, 2023, and the convening notice
shall be published in a newspaper empowered to publish legal
notices on May 3, 2023.
The documents provided for in articles R.22-10-23 of the French
Commercial Code, are available for consultation on the company’s
website mentioned below as of today, the twenty-first day prior to
the General Meeting: www.sensorion.com.
In accordance with articles R.225-83 of the French Commercial
Code, documents are available for the shareholders from the time
the meeting is convened. In accordance with applicable
regulations:
- any registered shareholders can, until the fifth day
(inclusive) before the Meeting, request from the Company to receive
these documents, including at their request, by way of an
electronic mail. For holders of bearer shares, the exercise of this
right is subject to the presentation of a certificate of attendance
in the bearer share accounts kept by the empowered
intermediary;
- any shareholder may consult these documents at the registered
office of the Company.
For any questions relating to the Annual General Meeting of May
24, 2023, shareholders are invited to send an email to
contact@sensorion-pharma.com.
The conditions for holding and taking part in this Combined
Shareholders’ General Meeting may evolve depending on the health,
regulatory and legal requirements in place. In general,
shareholders are invited to regularly consult the section dedicated
to the General Meeting on the Company's website
www.sensorion.com.
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of gene
therapies to restore hearing loss disorders, a significant global
unmet medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary
monogenic forms of deafness, developed in the framework of its
broad strategic collaboration focused on the genetics of hearing
with the Institut Pasteur. OTOF-GT targets deafness caused by
mutations of the gene encoding for otoferlin and GJB2-GT targets
hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The
Company is also working on the identification of biomarkers to
improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2
product: SENS-401 (Arazasetron) progressing in a planned Phase 2
Proof of Concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2022 full year financial report published on March
30, 2023, and available on our website and to the development of
economic conditions, financial markets, and the markets in which
Sensorion operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Sensorion to
be materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502006225/en/
Investor Relations David Lawrence, Chief Financial
Officer (US/UK) Noémie Djokovic, Investor Relations and
Communications (Europe/France) ir.contact@sensorion-pharma.com
International Media Relations Consilium Strategic
Communications Jessica Hodgson/Sue Stuart +44 7593 572720 +44 7561
424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024